F

Foseco India Ltd

Q4 FY26Chemicals & Petrochemicals

Foseco India Q4 FY26 earnings call: Revenue & Margins

Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.

Price₹6,468
Market cap₹5.0K Cr
P/E48.3
Updated25 Sept 2026
Read3 min read

Based on Foseco India Ltd's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

The presentation does not provide explicit quarterly revenue, sales, or volume figures or their year-on-year changes. The investor presentation does not explicitly provide quarterly EBITDA, operating margin, or PAT figures, nor year-on-year changes for a specific quarter.

From Foseco India Ltd's Q4 FY26 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • The presentation does not provide explicit quarterly revenue, sales, or volume figures or their year-on-year changes.
  • It reports FY 25-26 revenue from operations of INR 1,719 million for the acquired Morganite Crucible India Ltd (Page 13).
  • FIL’s overall revenue growth CAGR is stated as 15.6% over the last 4 years (Pages 5 and 6).
  • Profit after tax (PAT) CAGR is 27% over the last 4 years, indicating strong profitability growth (Pages 5 and 6).
  • The presentation highlights that FIL is growing 3x the market growth with continuous share gains (Page 5).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Foseco India Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation does not provide specific details on capex amounts, capacity expansions, or new plants/projects with explicit statuses or timelines. However, it mentions: - Strategic Priority (Page 22): Executing capex projects with speed and accuracy as part of Operational Excellence. - Continuous Improvement (Page 18): Execution of lean and Kaizen initiatives likely connected to operational upgrades. - Sustainability Initiatives (Page 16): Installation of in-house solar energy source (565kWP), representing an operational investment in green energy. No further explicit information on specific capex amounts, new plant construction, capacity expansions, or detailed project timelines is provided within the presentation.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Foseco India Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The investor presentation does not explicitly mention or report any figures or details related to order book, order inflow, or pending orders. It focuses primarily on financial performance, strategic priorities, market trends, innovation, operational excellence, and sustainability initiatives. Specific metrics related to order backlog or inflow are not provided in any of the 23 pages reviewed.

Foseco India Ltd — Quarterly revenue & net profit

Revenue Net profit
Dec 2024
Mar 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹33 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Foseco India Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Vipul Organics Ltd (Q4 FY26)

    Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…

  • Chemfab Alkalis Ltd (Q4 FY26)

    Chlor Alkali segment: ₹55.63 crore (down 1.21% YoY from ₹56.31 crore) . Key concall takeaways from Chemfab Alkalis Ltd's Q4 FY26 earnings call — and how it…

  • Sudarshan Pharma Industries Ltd (Q4 FY26)

    Revenue from Operations for Q4 March 2026: ₹220.92 Cr (Page 41) . Key concall takeaways from Sudarshan Pharma Industries Ltd's Q4 FY26 earnings call — and how…

  • Innovassynth Technologies (India) Ltd (Q4 FY26)

    Order book improved by approximately INR 60 crore during the quarter, indicating strong customer demand and revenue visibility. Key concall takeaways from…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Foseco India Ltd Q4 FY26 results?

The presentation does not provide explicit quarterly revenue, sales, or volume figures or their year-on-year changes. The investor presentation does not explicitly provide quarterly EBITDA, operating margin, or PAT figures, nor year-on-year changes for a specific quarter.

What is Foseco India Ltd share price analysis?

Foseco India Ltd currently shows a neutral. The stock trades at a P/E of 48.3 with a market cap of ₹5,033 Cr. Investors should review the full earnings analysis for detailed insights.

Is Foseco India Ltd planning capital expenditure?

The presentation does not provide specific details on capex amounts, capacity expansions, or new plants/projects with explicit statuses or timelines.

Keep Foseco India Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.